Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 646

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 646
---
 inaccurate and the breach or inaccuracy is incapable of being cured or is not cured within    
 the timeframes specified in the Merger Agreement.                                                |
| ● | By                                                                                               
 Denali if there has been a Material Adverse Effect (as defined in the Merger Agreement) on       
 Longevity and the Target Companies, taken as a whole, following the date of the Merger Agreement 
 which is uncured within the time frame specified in the Merger Agreement.                        |
| ● | By                                                                                               
 either Longevity or Denali if any of the required proposals fail to receive the requisite        
 vote for approval by Denali’s shareholders.                                                      |

First Amendment to the C&E Agreement

On January 25, 2023, the Company and each of its shareholders entered into an amendment to the C&E Agreement with Longevity pursuant to which certain provisions of the C&E Agreement were amended to, among other things: modify the aggregate valuation assigned to Longevity reflecting the Acquisition Transactions to match that agreed to in the Merger Agreement, modify the allocation of the transaction consideration among the Target Companies to match that agreed to in the Merger Agreement, modify the minimum cash balance at closing of the Business Combination to match that agreed to in the Merger Agreement, and, conform certain representations, warranties, covenants, closing conditions, termination provisions, and other provisions of the C&E Agreement to the Merger Agreement.

Second Amendment to the C&E Agreement

On June 26, 2023 the C&E Agreement was further amended to revise the definition of an Approved deSPAC Transaction to have a lock-up of 180 days for directors, officers and 5% or greater stockholders of the post-transaction company.

Third Amendment to the C&E Agreement

On August 29, 2023, the C&E Agreements were further amended to revise the definition of an Approved deSPAC Transaction to remove the minimum cash balance condition of $30 million.

Note 12 – Subsequent Events

The Company evaluated subsequent events
and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this
evaluation, the Company did not identify any subsequent events that would have required adjustment or disclosure in these financial statements.

| F-122 |

Item 20. Indemnification of Directors and Officers.

FutureTech is a Delaware corporation. Section 145 of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party (or is threatened to be made